GleamWall
中文EN

XBIT XBiotech Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1626878 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.9%
ROA-29.0%
ROIC (approx.)-193.7%
Asset turnover—

Leverage & solvency

Liabilities / assets3.5%
Debt / equity0.00x
Current ratio39.51x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$4.66M$5.30M$5.21M$25.36M$5.08M$5.34M$11.62M$7.82M
SG&A expense$663,000$850,000$1.07M$4.40M$967,000$1.00M$1.93M$927,000
Operating income-$5.32M-$6.15M-$6.27M-$29.75M-$6.05M-$6.34M-$13.55M-$8.75M
Pretax income-$4.42M-$6.68M-$5.46M-$26.82M-$5.91M-$1.73M-$10.86M-$10.55M
Income tax$35,000$46,000$49,000$76,000$102,000$28,000$29,000-$41,000
Net income-$4.46M-$6.73M-$5.50M-$26.89M-$6.01M-$1.76M-$10.88M-$10.51M
EBITDA-$5.07M-$5.84M-$5.94M-$29.38M-$5.62M-$5.90M-$13.11M-$8.31M
EPS (basic)-0.15-0.22-0.18—-0.20-0.06-0.36—
EPS (diluted)————————
Balance sheet
Cash & equivalents$105.04M$109.53M$115.46M$125.55M$147.37M$152.94M$155.90M$172.68M
Receivables————$450,000$480,000$480,000$700,000
Current assets$106.36M$111.16M$117.05M$126.95M$148.95M$154.89M$157.69M$174.57M
PP&E, net$22.25M$22.49M$22.79M$23.13M$23.47M$23.79M$24.18M$24.53M
Total assets$128.61M$133.65M$139.84M$150.08M$172.42M$178.68M$181.86M$199.09M
Current liabilities$2.69M$3.35M$3.00M$7.93M$3.56M$3.86M$5.41M$15.11M
Total liabilities$4.55M$5.19M$4.82M$9.73M$5.34M$5.62M$7.15M$16.82M
Shareholders' equity$124.06M$128.46M$135.02M$140.35M$167.08M$173.06M$174.71M$182.27M
Shares outstanding30.49M30.49M30.49M30.49M30.49M30.49M30.49M30.49M
Cash flow statement
Operating cash flow-$4.52M-$4.51M-$8.97M-$22.95M-$4.26M-$5.99M-$6.72M-$6.54M
Capital expenditure$12,000$0$0$34,000$110,000$51,000$94,000$84,000
Free cash flow-$4.53M-$4.51M-$8.97M-$22.99M-$4.37M-$6.04M-$6.81M-$6.62M
Investing cash flow-$17,000-$4,000$9,000-$34,000-$110,000-$51,000-$94,000-$84,000
Financing cash flow$0$0$0$0$0$0-$10.25M$283,000
Depreciation & amortization$252,000$302,000$332,000$378,000$427,000$439,000$442,000$439,000
Stock-based compensation$64,000$172,000$172,000$162,000$24,000$107,000$3.33M$628,000
Share buybacks———————$0

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.